Incyte Corporation

Incyte Corporation is a global biopharmaceutical company specializing in the discovery, development, and commercialization of targeted novel therapeutics for serious unmet medical needs. Founded in 2002 and headquartered in Wilmington, Delaware, the organization operates primary research and clinical development facilities across North America, Europe, and Asia. The company's therapeutic portfolio spans key medical franchises, including hematology, oncology, dermatology, and inflammation and autoimmunity. Core commercialized prescription pharmaceuticals and late-stage clinical compounds include Jakafi, Opzelura cream, Monjuvi, Pemazyre, Zynyz, and Niktimvo. Incyte's scientific research focuses on precision molecular targets such as JAK1/JAK2 pathways, FGFR rearrangements, PD-1 inhibition, and CSF-1R signaling. The biopharmaceutical manufacturer collaborates with international healthcare partners, clinical trial sponsors, and medical research institutions to advance transformative treatments. Operating with a global workforce of over 2,800 employees, Incyte delivers innovative small molecule drugs and biologic therapies to patients and healthcare providers worldwide.